Sino Biopharm and Boehringer sign deal with $358 million upfront, up to $7 billion in total
City News Service · · AI-summarised by FinFlash
Sino Biopharm agreed a deal with Germany's Boehringer Ingelheim worth $358 million upfront and up to $7 billion in option and milestone payments, City News Service reported. Elsewhere in China's healthcare sector, BeOne posted third-quarter net income of $384.7 million and raised its 2026 revenue forecast to as much as $7 billion from $6.8 billion, underlining continued global demand for Chinese biotech assets.
So What?
The deal adds to evidence that multinational pharma is sourcing assets from China. Hong Kong-listed biotech may gain from the licensing trend.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.